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INTRODUCTION 
 
Advanced liver cirrhosis is associated with a poor clinical outcome. 
Therefore, assessment of prognosis is important in the management of these 
patients. The Child-Pugh score has long been the most widely used specific 
scoring system in liver disease. In 2002, the Model for End-Stage Liver 
Disease (MELD) was introduced for patients undergoing transjugular 
intrahepatic portosystemic shunt. It is currently used to predict survival in 
patients awaiting liver transplantation. The MELD seems to be superior to the 
Child-Pugh score in prioritizing potential liver recipients according to 
mortality risk. However, it is only based on three laboratory variables, and thus 
does not take into account all prognostic factors that will impact on the 
survival of cirrhotic patients, notably complications due to portal hypertension. 
There is still a need for improvement of prognostic markers that could be 
easily integrated into the clinical management of these patients. Patients with 
liver cirrhosis frequently develop renal dysfunction. The hepatorenal syndrome 
(HRS), the most serious renal complication, is associated with an extremely 
short survival time.  
The HRS is characterized by renal arterial vasoconstriction, which may 
precede clinically manifest renal dysfunction. The intrarenal resistance index 
(RI) is the most frequently used parameter to assess intrarenal resistance and is 
calculated based on Doppler sonographic intrarenal measurements. It is 
routinely used to diagnose transplant rejection or renal artery stenosis.  The RI 
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is calculated as per the formula given below: (peak systolic frequency shift- 
lowest diastolic frequency shift)/peak systolic frequency shift.  
On average, renal RI is higher in cirrhotic patients.The normal value of 
RI is 0.60-0.70 and is measured at the arcuate arteries (corticomedullary 
junction) or interlobar arteries (adjacent to medullary pyramids). Increased 
intrarenal RIs in patients with liver cirrhosis, especially in the decompensated 
stage, have been described before as compared to healthy controls. Cirrhotic 
patients with elevated intrarenal RIs tend to develop the HRS, leading to a poor 
prognosis. In the current study, we prospectively investigated the course of 
intrarenal RIs in patients with liver cirrhosis and compared its prognostic 
impact with those of the MELD and the Child-Pugh scores. 
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AIMS AND OBJECTIVES 
 
1. To study the levels of renal resistive index in patients at various stages 
of liver cirrhosis. 
2. To compare the values between patients with compensated and 
decompensated cirrhosis 
3. To compare their prognostic impact with those of the Model for End-
Stage Liver Disease (MELD) and the Child-Pugh scores.  
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REVIEW OF LITERATURE 
Gross Anatomy 
Embryologically, the liver grows as a ventral diverticulum from the 
junction of foregut and the midgut into the ventral mesogastrium (the caudal 
part of the septum transversum; the cranial part forms the diaphragm). The 
same diverticulum forms the gallbladder and bile ducts as well. The 
ligamentum teres hepatis is the obliterated umbilical vein, which joins the left 
portal vein; the ligamentum venosum is the obliterated ductus venosus, which 
joins the left portal vein to left hepatic vein. 
The upper surface of the liver is percussed at the level of the fifth 
intercostal space. Superior, anterior, posterior and right surfaces of the liver are 
continuous with each other and are related to the diaphragm and anterior 
abdominal wall. 
The anterior surface is separated from the inferior (visceral) surface by a 
sharp anterior (inferior) border that is clinically palpable on deep inspiration. 
The inferior surface is related to the hepatic flexure (the area where the vertical 
ascending (right) colon takes a right-angle turn to become the horizontal 
transverse colon), right kidney, transverse colon, duodenum and stomach. The 
gallbladder straddles the undersurfaces of liver segments IVB and V. 
There is an H-shaped fissure on the inferior surface of the liver. The 
right vertical arm of the H is formed by the gallbladder anteriorly and the 
inferior vena cava (IVC) posteriorly; it is incomplete, with the caudate process 
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between the two. The left vertical arm of the H is formed by the ligamentum 
teres hepatis in front and the ligamentum venosum behind. 
The transverse limb of the H is the porta hepatis (hilum), a 5-cm 
transverse fissure (slit) on the undersurface of the liver with the quadrate lobe 
in front and the caudate lobe behind. It contains the common hepatic duct 
(CHD) in front and to the right, the proper hepatic artery in front and to the 
left, and the portal vein behind, enclosed in the hepatoduodenal ligament 
(HDL), composed of 2 layers of lesser omentum. 
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Anatomic Divisions 
Anatomically, the liver is divided into a larger right lobe and a smaller 
left lobe by the falciform ligament (see the image below). This division, 
however, is of no use surgically. From a surgical point of view, the liver is 
divided into right and left lobes of almost equal (60:40) size by a major fissure 
(Cantlie’s line) running from the gallbladder fossa in front to the IVC fossa 
behind. This division is based on the right and left branches of the hepatic 
artery and the portal vein (see the image below), with tributaries of bile 
(hepatic) ducts following. The middle hepatic vein (MHV) lies in Cantlie's 
line. The left pedicle (left hepatic artery [LHA], left branch of the portal vein, 
and left hepatic duct) has a longer extrahepatic course than the right. Each lobe 
is divided into 2 sectors. The right hepatic vein (RHV) divides the right lobe 
into anterior and posterior sectors; the left hepatic vein (LHV) divides the left 
lobe into medial (quadrate) and lateral sectors. While the falciform ligament 
and umbilical fissure mark the division between left lateral and left medial 
sectors on the surface of the liver, no surface marking is observed between 
right anterior and right posterior sectors. The posterior sector of the right lobe 
and the caudate lobe are not seen on a frontal view of the liver; the anterior 
sector of the right lobe forms the right lateral border in this view. 
The sectors are further divided into segments (after Couinaud); each 
segment has its own blood supply and biliary drainage. The anterior sector of 
the right lobe contains superior (VIII) and inferior (V) segments. The posterior 
sector of the right lobe has superior (VII) and inferior (VI) segments. The 
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medial sector of the left lobe (quadrate lobe, segment IV) is part of the left lobe 
from a surgical perspective but lies to the right of the midline; it is further 
divided into a superior subsegment (A) and an inferior subsegment (B) (note: 
Japanese surgeons call the superior subsegment B and inferior subsegment A). 
The lateral sector of the left lobe contains segments II and III. 
The caudate lobe (segment I) lies in the lesser sac on the inferior surface 
of the liver between the IVC on the right, the ligamentum venosum on the left, 
and the porta hepatis in front (see the image below). The caudate lobe has three 
parts: a left spigelian lobe, a paracaval part, and a caudate process that 
connects the caudate lobe to the right lobe. The caudate lobe receives 
numerous small branches from the right hepatic artery (RHA), the LHA, the 
portal vein, and the confluence; bile ducts drain similarly.  
 Caudate 'lobe' is not a lobe but a segment (I); left lateral 'segment' is not 
a segment but a sector including two segments (II and III). 
On computed tomography (CT), the portal vein branches (with the left 
being higher than right) divide the right and left lobes of the liver into superior 
and inferior halves. The superior half of liver is composed of (from right to 
left) segments VII, VIII, IVA and II; the inferior half is composed of (from 
right to left) segments VI, V, IVB and III. 
Accordingly, the right portal vein divides the posterior sector of the 
right lobe into segments VII (superior) and VI (inferior) and the anterior sector 
of the right lobe into segments VIII (superior) and V (inferior). The left portal 
vein divides the medial sector of the left lobe (quadrate lobe) into subsegments 
A (superior) and B (inferior) and the lateral sector of the left lobe into 
segments II (superior) and III (inferior). 
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Ligaments 
The falciform ligament (which divides the liver into a larger anatomical 
right lobe and a smaller anatomical left lobe) has 2 layers of peritoneum; it 
attaches the anterosuperior surface of liver to the anterior abdominal wall and 
diaphragm. The free edge of the falciform ligament contains the ligamentum 
teres hepatis (round ligament of the liver): the obliterated umbilical vein, which 
is attached to the inferior surface of the liver between segment IV on the right 
and segment III on the left. The ligamentum venosum (the obliterated ductus 
venosus) is attached to the inferior surface of the liver between the caudate 
lobe and the left lateral sector. 
The superoposterior surface of the liver has coronary and left triangular 
ligaments; between the 2 leaves of the coronary ligament to the right of the 
IVC is the bare area of the liver, which is in contact with the inferior vena cava 
and inferior surface of the diaphragm. The falciform ligament is continuous 
with the anterior layer of the coronary ligament. On the left, the anterior and 
posterior layers of the coronary ligament unite to form the left triangular 
ligament. On the right, the anterior and posterior layers of the coronary 
ligament unite to form the right triangular ligament. 
The posterior layer of the coronary ligament on the right side is called 
the hepatorenal ligament. The hepatorenal pouch is the area below the posterior 
layer of the right triangular and coronary ligament over the right kidney. The 
lesser omentum connects the liver with the lesser curvature of the stomach and 
the first part of the duodenum via hepatogastric and hepatoduodenal ligaments. 
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Inferior vena cava ligament is a bridge of tissue between posterior surface of 
right lobe and caudate lobe behind the inferior vena cava. 
Blood Supply 
The liver has a unique dual blood supply (about 1500 mL/min) both 
from the proper hepatic artery (20-40%) and from the portal vein. 
The celiac trunk (axis) comes off the anterior surface of the abdominal 
aorta at the level of T12 – L1 between the right and left crura of the diaphragm. 
It is a short structure (about 1 cm) that trifurcates into the common hepatic 
artery (CHA), the splenic artery, and the left gastric artery (LGA). 
The CHA runs toward the right on the superior border of the proximal 
body of the pancreas. After giving off the gastroduodenal artery (GDA) behind 
the first part of the duodenum above the neck of the pancreas, it continues as 
the proper hepatic artery in the HDL (the free edge of the lesser omentum) to 
the left of the bile duct and in front of the portal vein. In the hepatic hilum, it 
divides in a Y-shaped manner into the RHA and the LHA, with the RHA 
ascending behind the CHD; the cystic artery is usually a branch of the RHA. 
The portal vein, formed by union of the superior mesenteric vein (SMV) 
and the splenic vein behind the neck of the pancreas, collects blood from the 
gastrointestinal (GI) tract (SMV and inferior mesenteric vein [IMV]) and from 
the spleen and pancreas (splenic vein). It then ascends in the HDL behind the 
CBD and the proper hepatic artery and divides in a T-shaped manner into right 
and left portal vein branches in the hepatic hilum. The right portal vein divides 
14 
 
within the liver parenchyma into a vertical right anterior sectoral branch 
(which then divides into segmental V and VIII branches) and a horizontal right 
posterior sectoral branch (which then divides into segmental VI and VII 
branches). The left portal vein runs below the base of segment IV to which it 
gives off several small branches; it then enters the liver parenchyma where it 
divides into branches to segments IV, III, and II. 
The hilar plate is a condensation of fibroareolar tissue that lies on the 
undersurface of the hilum of liver, separating it from the biliovascular pedicle 
at the porta hepatis; it continues along the right and left portal pedicles as 
sleevelike sheaths. 
The left portal vein connects to the umbilical vein through the 
ligamentum teres hepatis and to the left hepatic vein through the ligamentum 
venosum. The portal venous system (2 groups of capillaries, one in the organ 
being drained and the other in the liver) has no valves. 
Portosystemic connections are present in the gastroesophageal area 
(between the esophageal tributary of the left gastric vein and the esophageal 
tributaries of the azygos vein), in the rectum (between the superior, middle, 
and inferior rectal veins), around the umbilicus (between the left portal, 
umbilical, and paraumbilical veins and the superficial and deep epigastric 
veins), and in the retroperitoneum (between the colic and splenic veins and 
renal and posterior parietal veins). 
The three hepatic veins (RHV, MHV, and LHV) are largely intrahepatic 
and lie on the posterior surface of the liver. The MHV and the LHV may join 
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to form a common trunk before draining into the IVC. The IVC lies on the 
posterior surface of the liver in a groove (or, sometimes, a tunnel) between the 
bare area on the right, the caudate lobe on the left, and the caudate process in 
front. 
CT Anatomy 
On contrast-enhanced CT scanning, the right hepatic vein (horizontal) 
lies between the right posterior sector and right anterior sector; the middle 
hepatic vein (vertical) lies between right anterior sector and segment IV; and 
the left hepatic vein lies between left medial sector and left lateral sector. 
Portal vein bifurcation into right and left branches separates the cranial 
segments (VII, VIII, IVa, II) from the caudal segments (VI, V, IVb, III).  
Microscopic Anatomy 
The surface of the liver is covered by visceral peritoneum (serosa), with 
a Glisson capsule underneath. At the porta hepatis, the Glisson capsule travels 
along the portal tracts (triads), carrying branches of the hepatic artery, the 
portal vein, and the bile ducts into the liver substance. 
Sinusoids are large-diameter capillaries lined by endothelial cells 
between rows of plates or cords of hepatocytes. Sinusoids also contain Kupffer 
cells of the reticuloendothelial system (RES). Each hexagonal lobule has a 
central portal tract with branches of the hepatic artery, the portal vein, and bile 
ducts, as well as a peripheral tributary of the hepatic vein. Bile canaliculi 
between hepatocytes drain into bile ductules in the portal triad. Bile ductules 
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then form several orders of intrahepatic bile ducts, in an arrangement 
resembling the twigs and branches of a tree. 
The left portal pedicle lies at the base of segment IV and has a long 
extrahepatic course. The right portal pedicle has a short extrahepatic course; it 
divides into a right anterior sectoral pedicle which lies in the gallbladder fossa 
and a right posterior sectoral pedicle, which lies in the Rouviere sulcus.  
In cirrhosis, the superoinferior span (between the upper percussible 
border and the lower palpable border) of the liver, which is normally 12-16 cm, 
is reduced. Caudate lobe hypertrophies can occur in cirrhosis. 
Lobar, sectoral, and segmental liver resection (ie, lobectomy, sectorectomy, 
and segmentectomy) can be performed (eg, right hepatic lobectomy [segments 
V-VIII], left hepatic lobectomy [segments II-IV], right posterior sectorectomy 
[segments VI, VII]). Liver lobes (right or left) can be removed from a live 
donor and transplanted to another person. Intraoperative ultrasonography may 
delineate intrahepatic blood vessels (eg, hepatic artery, portal vein, and hepatic 
vein) and bile ducts and is a very useful tool for liver resections. 
Liver has enormous capacity of regeneration; normal liver can tolerate 
major liver resections involving up to 70-75% of liver parenchyma. 
Liver cancer (hepatocellular carcinoma) drains into hepatic lymph nodes 
at the porta hepatis and into the lymph nodes in the hepatoduodenal ligament. 
A hepatocellular carcinoma is supplied mainly by the hepatic artery. 
Unresectable tumors can be treated with transarterial embolization (TAE), 
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transarterial chemo-embolization (TACE), and transarterial radio embolization 
(TARE). 
The liver has a dual (arterial and portal) blood supply. The hepatic 
artery can be ligated or embolized; the liver then gets its arterial blood supply 
from the diaphragm and abdominal wall through its ligaments and the bare 
area. 
Unilateral portal vein embolization results in atrophy of ipsilateral lobe 
and hypertrophy of contralateral lobe. This is useful before major liver 
resections to increase the functional liver remnant (FLR). 
Cirrhosis of liver 
Cirrhosis of liver is a continuous, progressive and anatomically diffuse 
process characterized by fibrosis and distortion of the liver parenchyma with 
formation of nodules, resulting in decreased function of the liver and increased 
resistance to flow of portal venous blood .This process of cirrhosis is generally 
irreversible in the late stages and liver transplantation is the only treatment 
option in the advanced stage. But it is to be noted that certain conditions 
causing cirrhosis may respond to treatment of the underlying cause even 
resulting in reversal of the process in the early stages .This peculiarity is seen 
in cirrhosis caused by hepatitis C, alcohol, iron overload and obesity. 
Cirrhosis is the end stage of chronic injury, inflammation and 
destruction and regeneration of the hepatocytes, inflicted by various 
conditions. The pathological features include the development of excessive 
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fibrosis along with nodular regeneration of the parenchyma, fmally 
culminating in complete alteration in the architecture, and blood flow through 
the liver. The induction of the process of fibrosis occurs with the” activation of 
hepatic stellate cells, leading to the formation of increased amounts of collagen 
and other extracellular matrix components”. As the function progressively 
decreases and portal hypertension develops secondary to the altered portal 
blood flow, various complications of cirrhosis set in and the survival of the 
patients is very much shortened. 
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In India and most of the developing countries, the most common etiologies for 
development of cirrhosis are: 
1. Alcoholic liver disease 
2. Viral hepatitis. 
Whereas in developed countries the common causes include: 
• Nonalcoholic fatty liver disease 
• Alcoholic cirrhosis 
• Viral cirrhosis (hepatitis C) 
• Other less frequent causes include: 
• Primary and secondary biliary cirrhosis 
• Autoimmune hepatitis 
• Primary sclerosing cholangitis 
• Wilson disease 
• Hemochromatosis 
• Type 4 glycogenosis 
• Alpha-1 antitrypsin deficiency 
• Galactosemia 
• Tyrosinemia 
• Idiopathic portal fibrosis 
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• Infection (e.g., brucellosis, syphilis, echinococcosis, schistosomiasis) 
• Polycystic liver disease 
• Right-sided heart failure 
• Veno-occlusive disease 
In some forms of liver disease, only a single etiological agent is 
responsible for development of cirrhosis such as in chronic viral hepatitis 
(hepatitis B and C and primary biliary cirrhosis. But in most of the cases 
additional cofactors also contribute to the progression to cirrhosis. For 
example, of the people with homozygous mutations of C282Y for 
hemochromatosis only a small fraction develop cirrhosis. Other factors such as 
age, sex, alcohol, obesity, iron intake may play a major role. Similar is the case 
with alcoholic liver disease and NASH. Causes of cirrhosis also interact 
Progression to cirrhosis happens in shorter duration in patients with hepatitis B 
or C who also drink excess alcohol. Age of the patient, immunological status, 
duration of the disease are other factors affecting the progression to cirrhosis. 
PATHOGENESIS 
“Induction of fibrosis occurs with activation of hepatic stellate cells to 
myofibroblasts resulting in the development of increased amounts of collagen 
and other components of the extracellular matrix leading to architectural 
distortion inturn resulting in decrease in function and mass.” 
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CLINICAL MANIFESTATIONS 
Patients may present to the clinic for the first time with the 
complications of cirrhosis or may be asymptomatic and incidentally be 
identified during medical checkup for unrelated causes or because of abnormal 
liver function tests. 
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In clinical terms, cirrhosis is classified in to 
• Compensated form and 
• Decompensated form. 
Decompensation is characterized by cirrhosis complicated by one or more 
following features like - jaundice, ascites, hepatic encephalopathy, bleeding 
varices. Ascites is usually the first sign of decompensation. Whereas these 
features and any complication secondary to portal hypertension is absent in 
compensated cirrhosis. This distinction clinically is very important because of 
the implication it has in the prognostication and treatment. Compensated 
cirrhosis patients have a ten year survival rate of 50% whereas decompensated 
patients have a survival rate of about 50% in 18 months. A decompensated 
patient may become compensated when the inciting cause or the precipitating 
cause is removed and thereby the prognosis may improve. 
COMPENSATED CIRRHOSIS 
At this stage, the cirrhotic process of the liver is not severe enough to 
alter the function significantly and so the patients may asymptomatic or present 
with non-localizing manifestations or may be picked incidentally due to 
alteration in biochemical parameters or imaging studies .Patients may have 
fatigue, anorexia, weight loss, flatulence dyspepsia, abdominal pain. On 
examination, palmar erythema, pedal edema, spider naevi, may point towards 
cirrhosis. Abdominal examination may reveal an epigastric mass which is the 
enlarged left lobe of the liver and splenomegaly. Biochemical tests are usually 
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within normal limits in this group. The most common LFT abnormality in this 
group include mildly elevated transaminases, or GUT. Confirmation is by liver 
imaging or liver biopsy. Factors like bacterial infection, trauma, or 
medications, surgery may precipitate decompensation in compensated cirrhosis 
DECOMPENSATED CIRRHOSIS 
 These patients present with ascites, jaundice, altered sensorium, 
bleeding manifestations. 
SYMPTOMS 
Presentation in these patients may be with features of jaundice, pedal 
edema, abdominal distension, Upper GI bleed most commonly melena, 
hematemesis, pruritus, altered sensorium ranging from sleep disturbances to 
florid confusion and coma because of hepatic encephalopathy. In women, 
menstrual irregularities are common due to anovulation .Men, may manifest 
hypogonadism in the form of impotence, loss of sexual drive, testicular atrophy 
and infertility. 
GENERAL EXAMINATION 
Decreasing blood pressure - with progression of cirrhosis, mean arterial 
pressure often decreases. Hypertensive patients may become normotensive. 
Patients can have mild fever (37.5 -38 C). This is probably because of 
bacteremia due to gram negative organisms. Ongoing hepatocyte necrosis, 
development of hepatocellular carcinoma may also contribute. 
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Jaundice (This happens once the functional impairment due to 
hepatocyte destruction has exceeded the process of regeneration. The deeper 
the jaundice, more severe is hepatic decompensation) 
Skin findings 
Bronze pigmentation of the skin may throw light on the etiology as it 
occurs in hemochromatosis. 
Presence of vascular spiders (arterial spiders/ spider naevi/ spider 
telangiectasia/ spider angioma). They are seen in distribution of venous 
drainage areas of superior vena cava. As liver function worsens, new spiders 
may appear. They are more frequently associated with alcoholic cirrhosis. 
They occur normally in pregnancy and in some normal individuals. 
Hepatopulmonary syndrome is characterized by multiple spiders and clubbing. 
Palmar erythema: palms are warm and red in colour especially over the thenar 
eminence, hypothenar eminence and the pulp of the fingem. 
Mechanism of both arterial spiders and palmar erythema may be due to 
estrogen excess. The estrogens are inactivated in the liver. Even though serum 
estradiol level is normal and serum free testosterone is reduced. Thus the high 
estradiol/free testosterone ratio may be attributed to these findings. 
Leukonychia (related to hypoalbuminemia) 
Clubbing can occur pan digitally especially with development of hepato 
pulmonary syndrome or in cystic fibrosis .Hypertrophic osteoarthropathy has 
also been observed. 
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Dupuytrens contracture may be present. This is characterized by 
thickened palmar fascia resulting from unorganized proliferation of the 
fibroblasts. 
Head and neck findings — Parotid enlargement, alopecia, fetor 
hepaticus, KF ring in the eyes due to Wilson’s disease may be present. 
Fetor hepaticus refers to the breath of the cirrhosis patients that has a 
sweet pungent nature. This is because of presence of mercaptans. 
Chestfindings - Gynecomastia in males may be seen along with other 
features of feminization like change in the male pattern of pubic hair, loss of 
axillary hair and chest hair. It is because the androstenedione that is 
synthesized by the adrenals gets aromatized in to estrone and finally in to 
estradiol in the adipose tissue. 
Abdominal findings - Abdominal examination may reveal the presence 
of ascites, hepatomegaly, splenomegaly. and dilated abdominal wall veins. 
Ascites - Ascites refers to excessive collection of peritoneal fluid .In massive 
ascites fluid thrill may be present where as in moderate ascites shifting dullness 
is to be elicited. If flanks are full it is probably due to ascites and not fat. 
Hepatomegaly - The cirrhotic liver may be enlarged, shrunken or normal 
sized. On palpation, consistency is firm and nodular. Features such as shape, 
consistency, tenderness are better appreciated on palpation as the estimation of 
liver size correlates less accurately with imaging studies. Presence of a 
palpable liver in cirrhosis usually signifies, alcoholic liver disease, primary 
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biliary cirrhosis hemochromatosis, transformation into hepatocellular 
carcinoma, Budd Chiari syndrome. 
Splenomegaly - Splenomegaly in cirrhosis is due to congestion resulting from 
portal hypertension .However, correlation between splenic size and portal 
pressure is poor implicating that there may be other contributing. 
Caput medusa - With the development of portal hypertension, the portal 
venous blood gets carried through the periumbilical veins in to the umbilical 
vein which becomes patent in cirrhosis .From there the blood drains in to the 
upper and lower abdominal veins that end up in systemic circulation .These 
veins become engorged and prominent .Thus the portal blood gets shunted to 
systemic circulation. This appearance resembles the head (caput) of the 
mythical Gorgon Medusa thus termed caput medusae. 
Dilated abdominal veins developing in SVC obstruction and IVC 
obstruction should be differentiated from dilated veins due to cirrhosis. In 
order to distinguish the cause of obstruction direction of flow is to be assessed. 
In IVC obstruction the flow is below upwards whereas in cirrhosis the flow of 
the blood is away from the umbilicus. However since these veins in both 
conditions may lack valves, the flow may be bidirectional and the test may be 
misleading. Moreover the dilated veins due to obstruction are more commonly 
seen in the back and loin 
Peptic ulcers occur in 11% of cirrhosis patients. Duodenal ulcers are 
more frequently encountered than gastric ulcers. Colonization by helicobacter 
pylori is higher in cirrhosis when compared to normal population. Abdominal 
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hernias are more common in patients with ascites. They should be repaired 
only if severe enough to cause mortality in alcoholics, associated chronic 
pancreatitis can be present which may relapse .So this should be considered a 
differential diagnosis in alcoholic cirrhosis presenting with abdominal pain. 
Neurologic findings - The presence of Asterixis or liver flap indicate the 
presence of hepatic encephalopathy. 
Genitourinary findings - Testicular atrophy in males. 
Endocrine changes 
Hyperglycemia occurs in about 80% of cirrhotic patients in the form of 
glucose intolerance. Only around 10-20% are hut diabetic. 
INVESTIGATIONS 
Liver function test abnormalities: 
Aminotransferases - In chronic hepatitis, ALT is increased more than 
AST .As hepatitis progresses to cirrhosis, AST becomes more elevated than 
ALT and thus the ratio of AST to ALT is reversed from <1 to greater than 1 .In 
cirrhosis patients the enzymes can.be within normal values or may become 
moderately elevated. 
• Alkaline phosphatase - Alkaline phosphatase enzyme is elevated 2 to 3 
times normal in cirrhosis. If elevated more than that, primary biliary 
cirrhosis or sclerosing cholangitis should be considered as the etiology. 
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• Gamma-glutamyl transpeptidase - Levels of GGT and alkaline 
phosphatase are usually proportionately elevated Disproportionately high 
levels of GUT will be seen in alcoholic liver disease. GUT present in the 
microsomes gets induced due to alcohol intake. 
• Bilirubin - In compensated stage of cirrhosis, the bilirubin levels are 
usually normal. Decompensation is characterized by increasing levels of 
bilirubin and it is one of the prognostic indicators used in Child Pugh 
score. 
• Albumin - Albumin is exclusively synthesized in the liver. With 
worsening cirrhosis, due to the decline in the synthetic function of the 
liver, albumin levels also fall. It is also one of the prognostic indicators 
for survival in child scoring system. 
• Prothrombin time - Most of the coagulation factors are synthesized in 
liver. Prothrombin time which measures the extrinsic coagulation 
pathway, is a marker for the synthetic function of the liver. Thus 
coagulopathy worsens as cirrhosis progresses. 
Serum electrolytes - Hyponatremia can occur in patients with ascites. 
Severity can be correlated with worsening cirrhosis. 
Hematologic abnormalities - Thrombocytopenia, anemia and leucopenia 
can occur. The earliest abnormality to occur is thrombocytopenia and it is a 
marker for the development of portal hypertension. Pancytopenia can even be 
the presenting feature in asymptomatic compensated cirrhosis. This is 
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sequestration of the cells in the enlarged spleen. Platelet count usually does not 
fall below 50,000.This does not per se cause bleeding but bleeding can get 
aggravated in the presence of coagulopathy 
Anemia in cirrhosis is mainly because of upper GI bleed. Anemia can 
also be present as a result of direct suppression of bone marrow by alcohol, 
sequestration and hemolysis, folate deficiency. 
Other abnormalities - In cirrhosis, the globulin levels are high. This is 
because of shunting of bacterial antigens in the portal venous blood which are 
normally filtered by the liver in to systemic circulation leading to induction in 
production of immunoglobulins. Marked elevations of IgG may point towards 
the presence of autoimmune hepatitis. 
Imaging studies: Cirrhosis can be diagnosed radiologically using 
ultrasound, portal vein Doppler, CT and MRI in specific cases. 
• Ultrasonography - Ultrasonography is a non-invasive routinely used 
investigation to diagnose cirrhosis. The size of the liver, the nodularity, 
the portal vein diameter, presence of ascites and splenomegaly can be 
assessed. Doppler studies to check the direction of blood flow in the 
portal vein aids in the diagnosis of portal hypertension. Presence HCC, 
portal vein thrombosis can also be made out. 
• CT is not the first choice in the diagnosis of cirrhosis.It may be useful 
when investigating liver malignancy or secondaries or pancreatic 
pathology. 
30 
 
• MRI may be useful in hemochromatosis to reveal iron overload. MRA 
can determine portal vein flow and dynamics 
• Elastography to assess the stiffness of the liver tissue is available. 
Liver biopsy 
The gold standard investigation for diagnosing cirrhosis is liver biopsy. 
Nowadays liver biopsy is rarely required to diagnose cirrhosis. 
Only certain situations may require performing liver biopsy such as for 
demonstrating the underlying metabolic cause of cirrhosis such as NASH, 
Wilson disease, hemochromatosis, and alpha 1 antitrypsin deficiency 
PROGNOSIS 
Child-Turcotte-Pugh Score (CTP): This simple scoring sys:n widely in 
use in clinical practice, for predicting the prognosis and nsiSkw from the major 
complications of the cirrhosis patients. Even though it derived based on 
statistically significant studies and is only derived in n empirical manner, this 
score can predict the outcomes in patients with hvdr cirrhosis with reasonable 
accuracy. 
31 
 
The parameters included are: 
Child-Turcofte-Pugh Classification for Severity of Cirrhosis 
 
Points* 
1 2 3 
Encephalopathy None Grade 1-2 (or precipitant induced) 
Grade 3-4 
(or chronic) 
Ascites None Mild to moderate (diuretic responsive) 
Severe 
(diuretic refractory) 
 
Bilirubin (mg/dL) <2 2 - 3 >3 
Albumin (gfdL) >3.5 2.8 – 3.5 <2.8 
INR <1.7 1.7 – 2.3 >2.3 
Class A = 5 to 6 points (least severe liver disease) 
Class B = 7 to 9 points (moderately severe liver disease) 
Class C 10 to 15 points (most severe liver disease) 
 
Initially this scoring system was used in the stratification of patients in 
to risk groups before taking them up for portosystemic shunt surgeries. Then in 
clinical practice this system was used to prioritize the patients to be taken up 
for liver transplantation (Child Pugh class B) but now this system has been 
replaced by MELD score for selection of patients for liver transplantation. 
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Model for End-stage Liver Disease (MELD) 
MELD score is a score derived methodologically in order to prognosticate the 
patients with cirrhosis and portal hypertension. This score is calculated based 
on three noninvasively obtained variables: serum bilirubin, serum creatinine 
and INR. 
Model for End Stage Liver Disease (MELD) Score 
MELD = 3.78 x Iog serum bilirubin (mg/dL) + 
11.20 X 109e INR + 
9.57 x loge serum creatinine (mg/dL) + 
6.43 (constant for liver disease etiology) 
NOTES 
• If the patient has been dialyzed twice within the Iast 7days,then the value for 
serum creatinine used should  be 4.0 
• Any vaIue less than one is given a value of 1 (ie. if bilirubin is 0.8,a value of 
1.0 is used) to prevent the occurrence of scores below 0 
 
Patients with cirrhosis are given priority for liver transplantation on this 
particular score in the United States. Patient with a score more than 10 is to be 
considered for liver transplantation. This scoring system has the advantage that 
it is completely objective for assessment of severity of the disease and does not 
result in inter observer variation. Moreover the score has a wider range of 
values and thereby severity can be graded more precisely. 
MAJOR COMPLICATIONS OF CIRRHOSIS 
With the progression of cirrhosis and development of portal 
hypertension. Various complications occur as a result of either the decreased 
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synthetic. Excretory, metabolic functions of the liver and also some secondary 
to portal hypertension. The various complications include. 
“Portal hypertension    Coagulopathy 
Gastroesophageal varices    Factor deficiency 
Portal hypertensive gastropathy   Fibrinolysis 
Splenomegaly, hypersplenism   Thrombocytopenia 
Ascites      Bone disease 
Spontaneous bacterial peritonitis   Osteopenia 
Hepatorenal syndrome    Osteoporosis 
Type 1      Osteomalacia 
Type 2      Hematologic abnormalities 
Hepatic encephalopathy    Anemia 
Hepatopulmonary syndrome   Hemolysis 
Portopulmonary hypertension   Thrombocytopenia 
Malnutrition      Neutropenia” 
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PORTAL HYPERTENSION 
Portal hypertension is defined as “the elevation of the hepatic venous 
pressure gradient (HVPG) to >5 mmHg”. 
Portal hypertension occurs as a result of two processes happening 
simultaneously: 
1) The altered architecture of the liver due to fibrosis and regenerating 
nodules, results in increased resistance to the flow of the portal blood 
2) Increased blood flow secondary to splanchnic vasodilatation 
This portal hypertension results in variceal bleeding and ascites. The 
causes of portal hypertension are divided into pre-hepatic, post hepatic and 
intra-hepatic causes. Pre-hepatic causes are thrombosis of portal vein and 
splenic vein thrombosis which results in development of sinistral hypertension 
or left sided portal hypertension. Post hepatic causes are those affecting the 
hepatic veins and venous drainage in to the heart. Conditions include Budd 
Chiari syndrome veno occlusive disease, constrictive pericarditis, chronic right 
sided congestion, restrictive cardiomyopathy. Intra-hepatic causes include pre 
– sinusoidal causes such as schistosomiasis, congenital portal fibrosis and post 
sinusoidal causes including veno-occlusive disease and cirrhosis causes 
sinusoidal form of portal hypertension. 
Clinically significant portal hypertension occurs in around 60%of 
cirrhosis patients. Portal vein thrombosis can occur secondary to cirrhosis per 
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se, pancreatitis, abdominal trauma and infection or hematological causes such 
as essential thrombocytosis, polycvthemia vera, Protein C and S deficiency. 
The primary complications of portal hypertension include ascites, 
bleeding varices and hypersplenism.one third of the patients with cirrhosis 
have gastric and oesophageal varices. Thus it has become mandatory to screen 
all patients with established cirrhosis for the presence of varices using upper GI 
endoscopy. The risk of variceal bleed depends on several factors like the 
varices size, severity of cirrhosis, tense ascites, and increased wedged hepatic 
vein pressure. In patients with liver cirrhosis the development of portal 
hypertension may be revealed by the presence of thrombocytopenia, 
appearance of an enlarged spleen, encephalopathy, development of ascites and 
esophageal varices with or without bleeding. CT or MRI abdomen can be 
performed in doubtful cases or interventional radiological procedure to 
determine the free and wed hepatic vein pressure and the gradient between the 
two can be fbund out It is normally 5 mm Hg and if more than 12 mm Hg it 
signifies increased risk of bleeding. Once bleeding occurs acute therapy is to 
arrest the bleed and then followed by prophylaxis against repeated bleeding. 
Acute management is with intravenous fluids and blood products and use of 
octreotide at a rate of 50-100 mic/hour. This is followed by endoscopic 
variceal band ligation till the varices are obliterated. Non selective beta-
blockers can be used as medical prophylaxis. If failing this mode of 
management, TIPS can be fried. 
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Splenomegaly results from congestion due to increased portal pressure. 
Hypersplenism with development of thrombocytopenia may be the first 
presentation of portal hypertension even before ascites may develop. 
ASCITES 
 Ascites occur as result of excessive accumulation of peritoneal fluid. It 
can be because of cirrhosis per se or may be due to spontaneous bacterial 
peritonitis or development of malignancy. 
Pathogenesis 
 The following mechanisms contribute to the occurrence of ascites in 
cirrhosis with portal hypertension. 
 The intrahepatic resistance is increased, causing increased portal 
pressure accompanied by vasodilatation in splanchnic arterial system due to 
release of vasodilatory substances such as nitric oxide. Resulting in increased 
portal inflow. Both these mechanisms cause increased production of splanchnic 
lymph. Intravascular volume depletion occurs due to splanchnic vasodilatation 
resulting in under filling in other vascular beds and this leads to increased 
activity of the renin angiotensin system .This leads to an increased release of 
aldosterone leading to sodium and water retention and thus peripheral edema 
and ascites. Decreased oncotic pressure due to hypoalbuminemia also 
contributes. Ascites may lead to hepatic hydrothorax also. 
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 When patients present with ascites for the first time, diagnostic 
paracentesis is to be done. In patients with cirrhosis the ascitic protein content 
in the ascites is very low, less than 1.1 g/dl. SAAG ratio (‘serum to ascites 
albumin gradient’) has now replaced the description of exudate or transudate. 
A SAAG ratio of more than 1.1 g/dl denotes that the cause of the ascites is due 
to portal hypertension. If less than 1.1 g/dl infection or malignancy has to be 
ruled out. Risk of SBP is high when the ascetic fluid protein content is very 
low. Presence of RBCs indicates the presence of malignancy, omental varices 
or traumatic tap. Ascitic fluid polymorphonuclear cell count, of more than 250 
cells/mic L indicates the presence of infection. 
 Patients with small amount of ascites are usually managed with 
restriction of salt in the diet. Patients should be advised to take not more than 2 
gram per day and avoidance of preserved foods. Patients with moderate ascites 
are treated with diuretics. Spironolactone is started at a dose of 100-200 
mg/day as a single dose and frusemide can be additionally prescribed at a dose 
of 40-80mg when peripheral edema is present. Dose of spironolactone can be 
escalated up to a dose of 400-600 mg and furosemide may be increased to 160 
mg till clinical response occurs. If ascites is still present with these dosage of 
diuretics and on a sodium compliant diet, the term refractory ascites is used. 
Treatment of refractory ascites or repeated large volume ascites is with 
intravenous albumin infusion and TIPS. Recent studies have showed that TIPS 
useful in managing ascites but has no mortality benefit. Once resistant ascites 
38 
 
develops the prognosis is bad, with survival rates not more than 50% at the end 
of two years. 
SPONTANEOUS BACTERIAL PERITONITIS 
SBP can occur in patients with cirrhosis and ascites due to infection of 
the ascitic fluid without an intraabdominal source, spontaneously. The bacteria 
may translocate from the intestines in to the mesenteric lymph nodes followed 
by bacteremia and seeding of ascites may be the mechanism behind SBP. 
Escherichia coli is the commonest organism cultured. Streptococcus viridians, 
enterococcus and staphylococcus aureus and other gram positive bacteria can 
also cause SBP. Usually SBP is monobacterial, if polymicrobial - perforation 
of viscus is to be considered. The diagnosis of SBP is made when absolute 
neutrophil count in the ascites is more than 250/micro liter .Patients presenting 
with fever, sudden increase in ascites, abdominal pain, and altered sensorium 
should be screened for SBP. Sometimes they may present without any of these 
features also. Treatment is with second generation cephalosporins. Prophylaxis 
1kw SBP is given to patients with prior history of SBP, very low proteins in 
ascitic fluid and in patients with upper GI bleeding. Once weekly antibiotic is 
given as prophylaxis. 
IIEPATIC ENCEPHALOPATHY 
Hepatic encephalopathy is otherwise called portosystemic 
encephalopathy. This is a complex syndrome of neuropsychiatric 
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manifestations with disturbances in conscious level and personality changes 
which fluctuate from day to day occurring either in chronic liver disease or 
fulminant hepatic failure. In acute liver injury the presence of encephalopathy 
is required for a diagnosis of fulminant hepatic failure. Encephalopathy 
happens more commonly in patients with cirrhosis. Gut-derived neurotoxins 
which are normally detoxified by the liver accumulates in the systemic 
circulation as detoxification function is lost in cirrhosis due to decreased mass 
of the liver and vascular shunting occurs. These neurotoxins are responsible for 
the symptoms of hepatic encephalopathy. Ammonia levels are elevated in CLD 
patients with hepatic encephalopathy, but the levels of ammonia cannot be 
used to predict the severity of the disease. Other compounds that are 
recognized as the development of encephalopathy include false 
neurotransmitters and mercaptans. 
 In acute liver failure, mental status changes can occur within weeks to m 
Cerebral edema is a feature of acute fulminant hepatic failure and does in 
happen with encephalopathy secondary to CLD .Care should be taken in 
prevent cerebral herniation and treatment should be instituted to decrease the 
cerebral edema with mannitol and judicious use of intravenous fluids. Certain 
factors can precipitate hepatic encephalopathy .These include SBP, 
hypokalemia, UGI bleed, increased dietary protein load .These factors should 
be looked for and corrected. Patients may be contsed or exhibit personality 
changes. They may even be violent and difficult to manage; alternatively 
patients may be very sleepy and difficult to rouse. The precipitating events 
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should be sought carefully. If patients have ascites diagnostic tapping to rule 
out SBP should be done. Any evidence of GI bleed should be sought, and 
patients should be appropriately hydrated. Electrolyte abnormalities should be 
corrected. In these patients clinically asterixis should be looked for. Asterixis 
can be elicited by having the patients extend their arms and bending their 
wrists backward. In this maneuver, patients who are encephalopathic may have 
a “liver flap”-i.e. a sudden forward movement of the wrist. This requires 
patients cooperation with the examiner and so cannot be elicited in those who 
are severely encephalopathic or in hepatic coma The diagnosis of hepatic 
encephalopathy is clinical and requires an experience clinician to recognize 
and put together all of the various features. 
 Treatment of hepatic encephalopathy includes management of the 
precipitating factors. Restriction of dietary protein which was considered in the 
past is now discouraged due to the negative impact it exerts. Vegetable 
proteins are preferred over animal proteins. The mainstay of treatment is to use 
lactulose a non-absorbable disaccharide, that causes acidic milieu in the colon 
and there by converts ammonia into ammonium and prevents the diffusion of 
ammonia produced in the gut in to portal system. It also alters the gut 
microbiome to a favorable milieu. The amount of lactulose ingested is titrated 
to a net result of achieving 2-3 soft stools per day. Antibiotics that are retained 
in the gut and not absorbed in to systemic circulation are preferred to sterilize 
the gut. Neomycin and metronidazole were used in the past .Their use became 
limited due to side effect such as ototoxicity and peripheral neuropathy. The 
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drug of choice now is Rifaximin at a dosage of 550 mg twice daily. 
Supplementing Zinc can also be tried. 
ABNORMALITIES OF COAGULATION 
Coagulopathy is almost universal in patients with cirrhosis. This is 
because the synthesis of coagulation factors is decreased and anticoagulants 
clearance from the system is impaired. In addition patients may have 
thrombocytopenia as a result of hypersplenism due to portal hypertension. 
Administration of parenteral vitamin K does not improve the clotting factors or 
the prothrombin time in cirrhosis patients. Platelet function is also abnormal 
apart from reduction in its number. 
BONE DISEASE IN CIRRHOSIS 
Osteoporosis can occur in cirrhosis and other liver diseases with 
predominant cholestatic picture due to Vitamin D malabsorption. The rate of 
bone resorption exceeds that of new bone formation in patients with cirrhosis, 
resulting in bone loss. Dual x-ray absorptiometry (DEXA) is a useful method 
for determining osteoporosis or osteopenia in patients with chronic liver 
disease. When a DEXA scan shows decreased bone mass, treatment should be 
administered with bisphosphonates that are effective at inhibiting resorption of 
bone and efficacious in the treatment of osteoporosis 
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HEPATORENAL SYNDROME 
Hepatorenal syndrome is the term attributed to the renal impairment 
which develops in patients with end stage liver cirrhosis or those with acute 
fulminant liver failure which is both reversible and only functional without any 
anatomical alteration. It is characterized by marked reduction in glomerular 
filtration rate and renal plasma flow (RPF), without any other contributing 
cause to renal failure. The pathophysiology behind HRS is severe 
vasoconstriction in the renal vascular bed with paradoxical peripheral arterial 
vasodilation. The function of the renal tubules is normal and there is no 
proteinuria or abnormal histology in the kidneys. 
HRS has been classified in to two types 
Type 1 HRS is defined as the “acute onset of rapidly progressive 
oliguric renal failure unresponsive to volume expansion with the doubling of 
serum creatinine value to more than 2.5 mg/dl within 2 weeks duration”. 
However as recently proposed a diagnosis of type 1 HRS should be considered 
whenever there is fulfillment of criteria defining acute kidney injury by an 
abrupt increase in serum creatinine more than or equal to 0.3 mg/dl or an 
increase of more than 1.5 times from the baseline. This is to ensure that 
treatment is not delayed unnecessarily, as baseline creatinine is a predictor of 
HRS reversal with vasoconstrictors 
Type 2 HRS progresses more slowly and the cut off of serum creatinine 
is 1.5 mg/dl. A precipitating factor frequently is identified in type 1 HRS, 
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whereas there are no such factors involved in development of type 2 HRS and 
it clinically manifests as refractory ascites. 
Pathophysiology 
 Hepatorenal syndrome occurs in the end stage of liver cirrhosis .The 
worsening of the renal function is because of severe vasoconstriction occurring 
at the level of renal blood vessels. However the cause for the development of 
this vasoconstriction is not fully understood .It has been suggested that this can 
be because of the imbalance that slowly starts developing between the renal 
vasoconstrictors and vasodilators. In type 2 HRS the mechanisms responsible 
for development of HRS are gradually progressive whereas in type 1 HRS, 
there is a sudden worsening of the kidney function due to inability of the 
compensatory mechanisms to maintain the perfusion in the renal arteries. The 
development of HRS is the end result of the interaction between these 
pathways: 
1. Splanchnic vasodilation with hyper dynamic circulation with 
consequent renal vasoconstriction; 
2. Activation of renal sympathetic nervous system (SNS 
3. Cardiac dysfunction that may result in decreased renal pcr&sion. 
4. Action of different vasoactive mediators and cytokines renal circulation. 
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Peripheral Arterial Vasodilation 
 In patients with cirrhosis and portal hypertension, there is increased 
production of certain vasodilating factors such as nitric oxide in the splat and 
to a lesser extent in systemic circulation .This results in splanchnic alt systemic 
vasodilatation and splanchnic blood pooling as there is also increased 
resistance to the flow of the portal blood through the fibrosed liver. Thus the 
effective circulating intravascular volume decreases and this results in 
stimulation of carotid baroreceptors and thereby increase in the activity of 
sympathetic nervous system (SNS). This and the decrease in the effective 
volume of renal blood flow stimulates the renin angiotensin aldosterone system 
(RAAS). Thus a hyper dynamic circulation results with decreased peripheral 
vascular resistance and renal vasoconstriction. With progression of cirrhosis, 
this process becomes a vicious cycle, as with further increase in splanchnic 
vasodilatation, worsens the renal vasoconstriction. 
Stimulation of the Renal SNS 
 Studies have shown that there are reflexes such as hepato renal reflex 
that may determine the renal vasoconstriction in response to increased pressure 
in hepatic sinusoids. This is mediated through the renal sympathetic system. 
1) Assay is costlier 
2) Assay needs further standardization. 
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3) The levels may be altered in infection and by drugs such as ACE 
inhibitors, steroids and calcineurin inhibitors. 
4) Cystatin C is also a marker for fibrosis progression in liver cirrhosis. 
This could represent a possible bias when interpreting the results. Thus 
its use is still not validated. 
Renal Doppler Ultrasonography 
 Renal vasoconstriction is the major pathology behind I This renal 
vasoconstriction can be assessed using Doppler ultrasound of the renal arteries 
by using an index called renal resistive index (RI).This value is derived from 
the spectral waveforms corresponding to the flow at the renal arteries and is 
determined using the formula 
Renal Resistive Index = Peak systolic frequency shift - Lowest diastolic frequency shift 
       Peak systolic frequency shift 
RI in cirrhosis is increased when compared to the normal population. 
And studies have shown that a high RI value (more than 0.7) can be 
documented in cirrhotic patients even in whom RFT is normal. 
 It has also been shown that normally RI exhibits a gradient decreasing 
from the hilum towards the outer cortex. In cirrhotic patients with diuretic 
responsive ascites this gradient is well maintained. Whereas as the severity 
increases and in cirrhotic patients with refractory ascites this gradient is lost 
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and the RI at the level of the cortex measured in interlobular arteries is also 
high suggesting renal cortex vasoconstriction. This happens even before serum 
creatinine begins to raise. Thus in cirrhotic patients an increased RI in spite of 
normal values of serum creatinine, implicates that they are at a greater risk for 
development of renal dysfunction and elevation of serum creatinine. With 
treatment of FIRS, RI value reduces. Similarly liver transplantation also 
decreases the RI. Thus renal RI assessed using Doppler ultrasound may be 
used as an early marker for renal impairment in cirrhosis patients. However 
raised RI does not differentiate whether the cause of renal dysfunction is due to 
vasoconstriction alone or if it is associated with intrinsic kidney damage. 
 Numerous studies have been conducted to evaluate the use of renal 
resistive index in cirrhosis patients to identify early renal dysfunction. 
 Early detection of renal vasoconstriction by Doppler ultrasound predicts 
future development of HRS in patients with cirrhosis. In a perspective study 
done by Platt eta! RI. HRS develops in 26% of patients with elevated resistive 
indices compared with 1% of those with normal indices (P < 0.001) and the 
probability that patients with high RI would subsequently develop HRS is 
55%. 
LIVER TRANSPLANTATION 
Liver transplantation is indicated for end-stage cirrhosis of all causes. In 
sclerosing cholangitis and Caroli’s disease (multiple cystic dilatations of the 
intrahepatic biliary tree), recurrent infections and sepsis associated with 
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inflammatory and fibrotic obstruction of the biliary tree may be an indication 
for transplantation. Because prior biliary surgery complicates,and is a relative 
contraindication for liver transplantation, surgical diversion of the biliary tree 
has been all but abandoned for patients with sclerosing cholangitis. In patients 
who undergo transplantation for hepatic vein thrombosis (Budd-
Chiarisyndrome), postoperative anticoagulation is essential; underlying 
myeloproliferative disorders may have to be treated but are not a 
contraindication to liver transplantation. 
              If a donor organ can be located quickly, before life-threatening 
complications - including cerebral edema set in, patients with acute liver 
failure are candidates for liver transplantation. Routine candidates for liver 
transplantation are patients with alcoholic cirrhosis, chronic viral hepatitis, 
and primary hepatocellular malignancies. Although all three of these 
categories are considered to be high risk, liver transplantation can be offered to 
carefully selected patients. Currently, chronic hepatitis C and alcoholic liver 
disease are the most common indications for liver transplantation, accounting 
for over 40% of all adult candidates who undergo the procedure. Patients with 
alcoholic cirrhosis can be considered as candidates for transplantation if they 
meet strict criteria for abstinence and reform; however, these criteria still do 
not prevent recidivism in up to a quarter of cases. Patients with chronic 
hepatitis C have early allograft and patient survival comparable to those of 
other subsets of patients after transplantation; however, reinfection in the donor 
organ is universal, recurrent hepatitis C is insidiously progressive, the impact 
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of antiviral therapy is limited, allograft cirrhosis develops in 20–30% at 5 
years, and cirrhosis and late organ failure are being recognized with increasing 
frequency beyond 5 years. In patients with chronic hepatitis B, in the absence 
of measures to prevent recurrent hepatitis B, survival after transplantation is 
reduced by approximately 10–20%; however, prophylactic use of hepatitis B 
immune globulin (HBIg) during and after transplantation increases the success 
of transplantation to a level comparable to that seen in patients with nonviral 
causes of liver decompensation. 
The specific oral antiviral drugs lamivudine, adefovir dipivoxil, and 
entecavir can be used both for prophylaxis against and for treatment of 
recurrent hepatitis B, facilitating further the management of patients 
undergoing liver transplantation for end-stage hepatitis B; most transplantation 
centers rely on a combination of HBIg and antiviral drugs to manage patients 
with hepatitis B.  Patients with nonmetastatic primary hepatobiliary tumors -
primary hepatocellular carcinoma (HCC), cholangiocarcinoma, 
hepatoblastoma, angiosarcoma, epithelioid hemangioendothelioma, and 
multiple or massive hepatic adenomata - have undergone liver transplantation; 
however, for some hepatobiliary malignancies, overall survival is significantly 
lower than that for other categories of liver disease. 
Most transplantation centers have reported 5-year recurrence-free 
survival rates in patients with unresectable HCC for single tumors <5 cm in 
diameter or for three or fewer lesions all <3 cm comparable to those seen in 
patients undergoing transplantation for non-malignant indications. 
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Consequently, liver transplantation is currently restricted to patients whose 
hepatic malignancies meet these criteria. Expanded criteria for patients with 
HCC are being evaluated. Because the likelihood of recurrent 
cholangiocarcinoma is very high, only highly selected patients with limited 
disease are being evaluated for transplantation after intensive chemotherapy 
and radiation. 
Thus in the current era where biochemical tests for detecting renal 
dysfunction in cirrhosis at an early stage, is not useful, renal artery Doppler can 
prove to be an important tool to assess the degree of renal impairment even 
before the disease manifests biochemically. Thus if picked up at an early stage, 
steps to prevent further worsening of renal function can be implemented. 
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MATERIALS AND METHODS 
STUDY POPULATION 
SOURCE OF DATA 
The study was conducted on 50 consecutive patients admitted to 
Government Rajaji Hospital & Madurai Medical College during the study 
period. 
Inclusion criteria 
Liver cirrhosis patients of any etiology as diagnosed by clinical, 
biochemical and imaging methods.  
Subgroups of patients included 
Patients with compensated cirrhosis (absence of ascites,hepatic 
encephalopathy, upper GI bleed) 
Patients with decompensated cirrhosis   
Exclusion criteria 
Patients with 
1. Diabetes 
2. Hypertension 
3. Nephrotoxic medication intake 
4. Acute GI bleeding and shock 
5. Ultrasonographic evidence of obstruction or parenchymal renal disease 
6. Sepsis 
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ANTICIPATED OUTCOME 
RENAL RESTITIVE INDEX is not inferior in sensitivity and 
specificity to the MELD/CTP score. 
DATA COLLECTION 
 Informed consent was obtained from all patients/patients caretakers for 
the study. In all the patients relevant information (detailed history with detailed 
clinical examination) was collected in a predesigned proforma. 
LABORATORY INVESTIGATIONS 
a) Complete blood count 
b) Liver function test (LFT) 
c) Renal function test (RFT) 
d) PT-INR 
e) Serum albumin 
f) Ultrasound abdomen 
g) Renal artery duplex Doppler 
 
DESIGN OF STUDY 
 Hospital based Prospective study. 
PERIOD OF STUDY 
 3 MONTHS (JULY 2017 to September 2017) 
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COLLABORATING DEPARTMENTS 
DEPARTMENT OF MEDICAL GASTROENTEROLOGY 
DEPARTMENT OF BIOCHEMISTRY 
DEPARTMENT OF RADIOLOGY 
ETHICAL CLEARANCE: Clearance obtained. 
CONSENT:  Individual/caretakers written and informed consent. 
ANALYSIS: Statistical analysis will be performed using appropriate tests as 
required according to data. 
CONFLICT OF INTEREST: NIL 
FINANCIAL SUPPORT:  SELF 
PARTICIPANTS:  
         50 LIVER CIRRHOSIS patients admitted in medical ward at 
Government Rajaji hospital, Madurai  
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OBSERVATION AND RESULTS 
TABLE 1: DISTRIBUTION OF AGE 
AGE No of Cases Percentage 
<30 6 12 
31 – 35 7 14 
36 – 40 20 40 
>40 17 34 
Total 50 100 
Mean 38.38 
SD 6.46 
  
 
CHART 1 AGE DISTRIBUTION IN STUDY POPULATION 
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COMMENTS 
About 40% of the study population were in the group of 36-40 years. 
About 34% of the study population were in the group of >40 years. 
About 14% of the study population were in the group of 31-35 years. 
About 12% of the study population were in the group of <30 years. 
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TABLE 2: SEX DISTRIBUTION IN THE STUDY POPULATION 
SEX No of Cases Percentage 
Male 36 72 
Female 14 28 
Total 50 100 
 
CHART 2: SEX DISTRIBUTION IN THE STUDY POPULATION 
SEX DISTRIBUTION
36
14
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COMMENTS 
About 72% of the study population were males and 28% were females.  
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TABLE 3: ETIOLOGY DISTRIBUTION IN THE STUDY 
POPULATION 
ETIOLOGY NO OF CASES PERCENTAGE 
Alcohol 26 52 
Auto Immune 1 2 
Cryptogenic 9 18 
Hepatitis B 13 26 
Wilson 1 2 
Total 50 100 
 
CHART 3 
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 COMMENTS 
      Alcohol was the most common cause of cirrhosis in the study 
population (52%).Followed by hepatitis B(26%). Other cyptogenic causes 
predominate next to alcohol and hepatitis B which was followed by 
autoimmune hepatitis and Wilson’s disease. 
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TABLE 4: SERUM BILURUBIN IN THE STUDY POPULATION 
T.BILIRUBIN NO OF CASES PERCENTAGE 
<1 7 14 
1.1 - 2.0 14 28 
2.1 - 4.0 12 24 
4.1 - 7.0 11 22 
>7 6 12 
Total 50 100 
Mean 3.56 
SD 3.01 
 
CHART 4 
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COMMENTS 
Mean bilirubin among the study population was 3.56. 
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TABLE 5: SERUM CREATININE IN STUDY POPULATION 
S.CREATININ No of Cases Percentage 
<1 26 52 
1.0 - 2.0 14 28 
2.1 - 4.0 6 12 
4.1 - 7.0 4 8 
>7 0 0 
Total 50 100 
Mean 1.5 
SD 1.33 
 
CHART 5 
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COMMENTS 
Mean creatinine among the study population was 1.5. 
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TABLE 6: PT-INR IN THE STUDY POPULATION 
 
PT INR No of Cases Percentage 
<1 14 28 
1.0 - 2.0 20 40 
2.1 - 4.0 10 20 
>4.0 6 12 
Total 50 100 
Mean 1.96 
SD 1.3 
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TABLE 7: SERUM ALBUMIN IN THE STUDY POPULATION 
 
ALBUMIN No of Cases Percentage 
<2 8 16 
2.1 - 3.0 18 36 
3.1 - 4.0 14 28 
>4.0 10 20 
Total 50 100 
Mean 3.05 
SD 0.92 
 
CHART 7 
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TABLE 8: ASCITES IN THE STUDY POPULATION: 
 
ASCITES No of Cases Percentage 
None 15 30 
Yes(2) 14 28 
Yes(3) 21 42 
Total 50 100 
 
CHART 8 
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COMMENTS 
Around 70% of patients in the study population had ascites.In this 28% 
of patients had grade 2 ascites according to CTP classification.42% of patients 
had grade 3 ascites. 
64 
 
TABLE 9: HEPATIC ENCEPHALOPATHY IN THE STUDY 
POPULATION 
Hepatic encephalopathy No of Cases Percentage 
Yes(I) 1 2 
Yes(II) 2 4 
Yes(III) 4 8 
Yes(IV) 1 2 
None 42 84 
Total 8 16 
 
CHART 9 
 
COMMENTS 16% of the total patients had hepatic encephalopathy.8% of 
patients in grade 3 followed by 4% had grade 2 and 2% in grade 1 and 2% in 
grade 4 hepatic encephalopathy. 
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TABLE 10: RESISTIVE INDEX (RI) VS MELD SCORE: 
RI Mean (MELD) SD 
<0.7  (30) 9.5 2.53 
>  0.7  (20) 31.5 8.12 
p value <0.001 Sig  
Correlation  coefficient 0.903 
Very Good correlation between RI and Meld 
 
CHART 9 
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COMMENTS 
While compared RI with MELD SCORE mean MELD in patients with 
RI <0.7(30 patients) was 9.5 and in patients with RI>0.7(20 patients) was 31.5. 
Correlation coefficient was 0.903 indicates very good correlation.p value was 
<0.001. 
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TABLE 10: MELD SCORE 
MELD No of Cases Percentage 
<10 15 30 
10 - 15 14 28 
16 – 25 7 14 
26 – 40 11 22 
>40 3 6 
Total 50 100 
Mean 18.32 
SD 12.18 
 
TABLE 11: CHILD-PUGH SCORE 
Child pugh No of Cases Percentage 
5A 15 30 
7B 7 14 
8B 4 8 
9B 3 6 
10C 3 6 
11C 1 2 
12C 1 2 
13C 9 18 
14C 3 6 
15C 4 8 
Total 50 100 
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TABLE 12: RENAL RESISTIVE INDEX (RI) VS CHILD-PUGH SCORE 
 
RI Mean CHILD-PUGH SCORE SD  
<0.7  (30) 6.43 1.61  
>  0.7  (20) 13.1 1.48  
p value <0.001 Sig   
Correlation  coefficient 0.873 
Very Good correlation between RI and Child pugh 
 
CHART 10 
 
 
 
 
 
 
 
COMMENTS 
While compared RI with CHILD-PUGH SCORE mean CHILD-PUGH 
SCORE in patients with RI <0.7(30 patients) was 6.43 and in patients with 
RI>0.7(20 patients) was 13.1. Correlation coefficient was 0.873 indicates very 
good correlation.p value was <0.001. 
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TABLE 13: COMPENSATED VS DECOMPENSATED FORM: 
 
 
Compensation Status No of Cases Percentage 
Compensated 15 30 
Decompensated 35 70 
Total 50 100 
 
 
RI vs Status Compensated DC 
<0.7  (30) 12 18 
>  0.7  (20) 3 17 
3/30 vs 12/30  
p value <0.001 Sig  
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CHART 11 
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COMMENTS 
RI was >0.7 in 17 liver cirrhosis patients with DECOMPENSATED 
FORM while RI >0.7 in only 3 patients with COMPENSATED FORM.P value 
was <0.001. 
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TABLE 14: RI IN DEATH VS ALIVE PATIENTS: 
 
Status No of Cases Percentage 
Death 8 16 
Alive 42 84 
Total 50 100 
 
 
RI vs Status Death Alive 
<0.7  (30) 0 30 
>  0.7  (20) 8 12 
0/30 vs 8/20  
p value <0.001 Sig  
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CHART 12 
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COMMENTS 
At the end of 3 months of registration, patient’s clinical status was 
reviewed. 8 patients were died.All the 8 patients had RI>0.7.P value was 
<0.001. RENAL RESISTIVE INDEX correlated strongly with short term in-
hospital mortality 
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DISCUSSION 
 
In total 50 patients about 40% of the study population were in the group 
of 36-40 years. About 34% of the study population were in the group of >40 
years. About 14% of the study population were in the group of 31-35 years. 
About 12% of the study population were in the group of <30 years. About 72% 
of the study population were males and 28% were females. Alcohol was the 
most common cause of cirrhosis in the study population (52%).Followed by 
hepatitis B(26%). Other cyptogenic causes predominate next to alcohol and 
hepatitis B which was followed by autoimmune hepatitis and Wilson’s disease. 
Mean bilirubin among the study population was 3.56.  Mean creatinine among 
the study population was 1.5. 
Around 70% of patients in the study population had ascites.In this 28% 
of patients had grade 2 ascites according to CTP classification.42% of patients 
had grade 3 ascites. 
16% of the total patients had hepatic encephalopathy.8% of patients in 
grade 3 followed by 4% had grade 2 and 2% in grade 1 and 2% in grade 4 
hepatic encephalopathy. 
While compared RI with MELD SCORE mean MELD in patients with 
RI <0.7(30 patients) was 9.5 and in patients with RI>0.7(20 patients) was 31.5. 
Correlation coefficient was 0.903 indicates very good correlation.p value was 
<0.001. 
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While compared RI with CHILD-PUGH SCORE mean CHILD-PUGH 
SCORE in patients with RI <0.7(30 patients) was 6.43 and in patients with 
RI>0.7(20 patients) was 13.1. Correlation coefficient was 0.873 indicates very 
good correlation.p value was <0.001. 
RI was >0.7 in 17 liver cirrhosis patients with DECOMPENSATED 
FORM while RI >0.7 in only 3 patients with COMPENSATED FORM.P value 
was <0.001. 
At the end of 3 months of registration, patient’s status was reviewed. 8 
patients were died. All the 8 patients had RI>0.7.P value was <0.001. RENAL 
RESISTIVE INDEX correlated strongly with short term in-hospital mortality 
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CONCLUSION 
RI is not inferior in sensitivity and specificity to the existing hepatic 
scoring systems like MELD and CTP SCORE. 
MELD score is based on easily measured variables (prothrombin time, 
bilirubin and creatinine).Serum creatinine is an indicator of impaired renal 
function. However, it has disadvantages as it depends on muscle mass and 
physical activity. Therefore renal function based on serum creatinine can be 
overestimated in patients with advanced cirrhosis. 
Thus, it is still necessary to develop improved prognostic markers 
feasible in daily practice. 
Our study confirms that the RI, based on sonographic measurements of 
intrarenal resistance, is an effective,noninvasive, economical functional test 
that provides useful information for the prognosis and management of cirrhotic 
patients. 
Elevated RIs may even disclose progress of the liver disease before 
changes in laboratory results.  
Therefore, the RI may help identify a subgroup of high-risk patients 
with a poor prognosis that require special therapeutic care. 
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PROFORMA 
Name: 
Age / Sex: 
Occupation: 
Presenting complaints 
H/O jaundice 
H/O abdominal distension/pedal edema 
H/O hematochezia/melena/hematemesis 
H/O altered sensorium/altered sleep habit 
H/O fever 
H/O abdominal pain 
H/O oliguria/dysuria/hematuria 
Past History: 
H/o DM, HT, CKD, CVD, DRUG INTAKE, CAD, Thyroid disorders, CLD, 
renal transplantation and blood transfusion. 
PERSONAL HISTORY 
Alcohol intake/smoking/high risk behavior 
Clinical Examination 
General Examination 
Consciousness,  
Orientation to time, place, person 
Pallor,  
Jaundice,  
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Clubbing,  
Lymphadenopathy,  
Hydration status 
Pedal edema 
Other signs of hepatocellular failure    
Vitals 
 PR 
 BP 
 RR 
 SpO2 
          Urine output 
Systemic examination 
CVS: 
RS: 
ABDOMEN 
           Presence of distended and dilated veins 
           Direction of flow 
           Free fluid 
           Hepatomegaly/splenomegaly 
CNS:              
Laboratory investigations 
a) Complete blood count, 
b) Renal function test, 
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c) Liver function test, 
d) PT-INR 
e) Serum albumin 
f) ultrasonography abdomen 
g) Renal artery duplex doppler 
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S.No Name Age Sex Etiology T.Bilirubin S.Creatinin PT INR Albumin Ascites HE RI MELD Child pugh status Status 
1 Ramasamy 42 M alcohol 1.0 0.9 1.1 4.5 None None 0.64 7 5A DC   
2 femina 40 F Alcohol 0.8 0.9 0.9 4.6 None None 0.58 6 5A DC   
3 Radha 48 F Hepatitis B 1.0 1.1 1.1 4.2 None None 0.57 8 5A DC   
4 Mohan 42 M Cryptogenic 1.1 1.0 1.2 4.5 None None 0.65 9 5A DC   
5 Rajkumar 36 M Alcohol 1.2 0.9 1.3 4.4 None None 0.66 10 5A C   
6 Kannaiya 37 M Hepatitis B 1.1 0.8 0.9 3.7 None None 0.58 7 5A DC   
7 Ilakkiyakumar 31 M Alcohol 1.0 0.6 1 4.3 None None 0.65 6 5A C   
8 Kanthasamy 40 M Alcohol 0.6 0.8 1.2 3.7 None None 0.66 8 5A C   
9 Irulayee 32 F Hepatitis B 1.3 1.0 1.1 3.9 None None 0.64 8 5A DC   
10 Muthumohan 35 M Alcohol 1.2 0.8 0.8 4 None None 0.62 7 5A C   
11 Kasimayan 35 M Alcohol 1.3 0.7 1.4 4.1 None None 0.63 11 5A DC   
12 Irulappan 46 M Hepatitis B 1.2 1.1 1.3 4.2 None None 0.65 11 5A DC   
13 Aiyasamy 40 M Alcohol 1.3 0.9 1.2 4.5 None None 0.64 9 5A DC   
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14 Ragu 42 M Hepatitis B 0.9 0.7 1 3.6 None None 0.65 6 5A C   
15 Vellapan 48 M Alcohol 0.8 0.8 0.9 4.2 None None 0.66 6 5A DC   
16 Rasu 36 M Alcohol 2.2 1.0 1.2 3.5 Yes(2) None 0.68 11 8B DC   
17 Gomathi 40 F Hepatitis B 1.8 0.9 1.3 3 Yes(2) None 0.64 12 7B C   
18 Vellaisamy 38 M Alcohol 1.5 0.8 0.9 2.8 Yes(2) None 0.66 8 7B C   
19 Magesh 31 M Hepatitis B 2.4 0.7 0.8 2.9 Yes(2) None 0.65 10 8B DC   
20 Jeyakumar 32 M Alcohol 3.6 0.9 1.1 3 Yes(3) None 0.67 12 10C C   
21 Muthumari 39 F Hepatitis B 4.2 1.2 1.2 3.2 Yes(2) None 0.68 16 9B DC   
22 Solaiyappan 40 M Alcohol 2.5 1.1 1.4 3.4 Yes(3) None 0.64 15 9B DC   
23 Murugesh 41 M Hepatitis B 1.1 0.9 1.3 2.8 Yes(2) None 0.69 10 7B DC   
24 Muthu 38 M Alcohol 2.4 0.7 0.9 3.1 Yes(2) None 0.65 10 8B C   
25 Kothandaraman 39 M Alcohol 1.4 0.6 1 3.2 Yes(2) None 0.67 8 7B DC   
26 Subburaju 38 M Alcohol 1.8 0.7 1.3 3 Yes(2) None 0.68 12 7B DC   
27 Mariyammal 48 F cryptogenic 1.2 0.8 1.4 3.1 Yes(2) None 0.69 11 7B C   
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28 Vignesh 37 M Alcohol 2.1 0.9 1 3.2 Yes(2) None 0.68 9 8B DC   
29 Radhammal 46 F Cryptogenic 3.2 1.0 0.9 3.5 Yes(2) None 0.67 11 9B C   
30 Alagu 39 M Alcohol 2.4 1.1 1 3.7 Yes(2) None 0.66 11 7B C   
31 Raji 19 F Auto immune 7.0 1.2 3.1 2.1 Yes(3) Yes(I) 0.74 28 14C DC   
32 Chokkalingam 30 M Alcohol 3.2 1.1 2 2.8 Yes(2) None 0.7 20 10C DC   
33 Anitha 28 F Cryptogenic 7.8 1.0 3.4 2.2 Yes(3) None 0.74 28 13C DC   
34 Jothi 30 F Hepatitis B 14.2 0.9 5.8 2.1 Yes(3) Yes(III) 0.76 36 15C DC Death 
35 Nageshwaran 32 M Alcohol 10.8 0.8 4.2 2 Yes(3) Yes(III) 0.71 31 15C DC Death 
36 Muniyammal 37 F Cryptogenic 4.4 0.7 2.6 3 Yes(3) None 0.72 23 12C DC   
37 Logappan 36 M Alcohol 2.5 0.8 1.8 2.9 Yes(3) None 0.7 16 10C C   
38 Veeran 25 M Wilson 3.5 0.9 2.9 2 Yes(3) None 0.71 23 13C DC   
39 Ballayya 41 M Cryptogenic 4.2 1.0 3 2.1 Yes(3) None 0.73 24 13C C   
40 Lingappan 43 M Alcohol 6.5 1.1 4.8 2.2 Yes(3) Yes(II) 0.74 32 14C DC Death 
41 Pandiselvi 41 F Hepatitis B 5.9 4.5 3.2 1.5 Yes(3) None 0.77 39 14C DC Death 
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42 Neppolian 46 M Alcohol 8.5 2.6 4.8 2.2 Yes(3) Yes(III) 0.79 41 13C DC   
43 Karthik 39 M Cryptogenic 5.4 3.6 2.9 2.1 Yes(3) None 0.8 37 13C C   
44 Rasukutty 49 M Alcohol 8.5 2.9 4.2 1.7 Yes(3) None 0.76 41 13C DC   
45 Alagukannu 48 F Hepatitis B 7.0 6.2 3.2 1.6 Yes(3) None 0.77 40 13C DC Death 
46 Vaitheeswaran 39 M Alcohol 3.5 3.7 0.9 1.8 Yes(3) None 0.78 24 11C DC   
47 Kadhar baasha 44 M Hepatitis B 6.0 5.3 3.2 2.2 Yes(3) None 0.81 39 13C DC Death 
48 Alex 48 M Alcohol 5.5 2.8 1.6 1.9 Yes(3) Yes(IV) 0.79 28 13C DC   
49 Veeralakshmi 39 F Cryptogenic 6.5 4.2 3 1.8 Yes(3) Yes(II) 0.82 39 15C DC Death 
50 Dhanapal 29 M Cryptogenic 7.8 3.5 4.2 2.4 Yes(3) Yes(III) 0.8 42 15C DC Death 
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